Clinical Trial Detail

NCT ID NCT03102606
Title Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors BeyondSpring Pharmaceuticals Inc.
Indications

breast cancer

prostate cancer

lung non-small cell carcinoma

Therapies

Plinabulin

Pegfilgrastim

Age Groups: adult senior

No variant requirements are available.